WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

12,575

Sector

Biotechnology & Medical Research

Calendar

08-25 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
18/07/25	28.55 $	+0.88%	37,967,540
17/07/25	28.30 $	+4.04%	57,878,000
16/07/25	27.20 $	-0.37%	39,023,010
15/07/25	27.30 $	+2.06%	46,659,580
14/07/25	26.75 $	+0.38%	38,433,120

Delayed Quote Hong Kong S.E., July 18, 2025 at 04:08 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

AAA

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.12CNY

Average target price

27.52CNY

Spread / Average Target

+5.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 16:08:35 18/07/2025 HKT			5-day change	1st Jan Change
28.55 ^HKD	+0.88%		+7.13%	+62.59%

07-16	Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.23 From HK$34.36, Keeps at Buy	MT
06-30	WuXi Biologics Launches Next-Generation Platform WuXiHigh??2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	CI

Capitalization	106B 116B 14.8B 12.7B 11.83B 11.01B 20.32B 1,275B 22.68B 143B 53.97B 598B 55.53B 54.38B 2,197B	P/E ratio 2025 *	27.1x	P/E ratio 2026 *	23x
Enterprise value	101B 111B 14.09B 12.09B 11.26B 10.48B 19.34B 1,213B 21.59B 136B 51.37B 569B 52.85B 51.75B 2,091B	EV / Sales 2025 *	4.77x	EV / Sales 2026 *	4.09x
Free-Float	86.37%	Yield 2025 *	-	Yield 2026 *	-

Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.23 From HK$34.36, Keeps at Buy	07-16	MT
WuXi Biologics Launches Next-Generation Platform WuXiHigh??2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-30	CI
US-China Tensions Cause Delay in Chinese Drug Research Projects, Sources Say	06-18	MT
China pharma projects disrupted by Sino-US tensions	06-18	RE
Hong Kong Stocks Edge Higher Despite Mixed China Data; Wuxi Biologics Drops on Stake Sale	06-16	MT
WuXi Biologics Shareholder to Offload 2% Stake via Block Trade; Shares Slide 6%	06-16	MT
Wuxi Biologics Announces Placing Of Existing Shares By Substantial Shareholder	06-16	RE
WuXi Biologics Kicks Off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu	06-09	CI
Wuxi Biologics Inc. Announces Directorate Changes, Effective June 6, 2025	06-06	CI
Wuxi Biologics Appoints Sherry Xuejun Gu As An Executive Director	06-06	RE
WuXi Biologics Grants 64,117 Restricted Shares Under Incentive Scheme	06-05	MT
Hong Kong Stocks Jump as US Court Blocks Trump's Tariffs; WuXi Biologics Surges 10%	05-29	MT
Terumo Says It And Wuxi Biologics Enter Into Agreement On A Drug Product Plant In Leverkusen, Germany	05-14	RE

Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.23 From HK$34.36, Keeps at Buy	07-16	MT
Jefferies Adjusts WuXi Biologics (Cayman)'s Price Target to HK$45 From HK$35, Keeps at Buy	03-31	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.36 From HK$30.59, Keeps at Buy	03-26	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy	02-20	MT
UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23	02-04	MT

WuXi Biologics (Cayman) Inc. Stock

Equities

2269

KYG970081173

Biotechnology & Medical Research

Valuation: WuXi Biologics (Cayman) Inc.

Chart: WuXi Biologics (Cayman) Inc.

Latest news: WuXi Biologics (Cayman) Inc.

Last Transcript: WuXi Biologics (Cayman) Inc.

Analysts' recommendations: WuXi Biologics (Cayman) Inc.

Press Releases: WuXi Biologics (Cayman) Inc.

News in other languages: WuXi Biologics (Cayman) Inc.

Quotes and Performance

Course Extremes

Managers and Directors: WuXi Biologics (Cayman) Inc.

ETFs: WuXi Biologics (Cayman) Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

WuXi Biologics Launches Next-Generation Platform WuXiHigh2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-30	AQ
WuXi Biologics Cayman : Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-30	PU
WuXi Biologics Cayman : Included in MSCI Selection Indexes for Third Consecutive Year	06-20	PU
Construction begins on new WuXi microbial manufacturing site	06-10	AQ
WuXi Biologics Cayman : and Virogen Biotechnology Establish Commercial Manufacturing Partnership	06-09	PU

La china WuXi Biologics venderá a Merck sus instalaciones de vacunas en Irlanda por 500 millones de dólares	01-06
MÄRKTE ASIEN/Honkgong nimmt wieder Fahrt nach oben auf	04/10/24
MÄRKTE ASIEN/Uneinheitlich - Anleger halten sich vor US-Daten zurück	10/09/24
MÄRKTE ASIEN/Etwas fester - US-Biotech-Gesetz belastet in China	10/09/24
MÄRKTE ASIEN/Yen auf 34-Jahres-Tief stützt Kurse in Tokio	27/03/24

1 day	+0.88%
1 week	+7.13%
Current month	+11.31%
1 month	+14.89%
3 months	+39.27%
6 months	+58.96%
Current year	+62.59%

1 week	26.35	28.9
1 month	23.1	28.9
Current year	15.62	29.3
1 year	10.14	29.3
3 years	10.14	82.95
5 years	10.14	148
10 years	8.33	148

Manager	Title	Age	Since
Zhi Sheng Chen CEO	Chief Executive Officer	53	01/01/2016
Ming Tu DFI	Director of Finance/CFO	55	23/08/2021
Ji Jie Gu CTO	Chief Tech/Sci/R&D Officer	58	-

Director	Title	Age	Since
Ge Li CHM	Chairman	57	01/02/2014
Zhi Sheng Chen BRD	Director/Board Member	53	01/02/2014
Yan Ling Cao BRD	Director/Board Member	40	01/05/2016

Name	Weight	AuM	1st Jan change
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	9.62%	0 M€	-19.71%	-
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD	4.23%	0 M€	-3.45%	-
CIMB FTSE CHINA 50 ETF - MYR	2.99%	1 M€	+14.50%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
WUXI BIOLOGICS (CAYMAN) INC.	+0.88%	+7.13%	+154.00%	-62.61%	14.8B
ARGENX SE	+0.24%	+2.39%	+15.57%	+35.09%	35.09B
WUXI APPTEC CO., LTD.	+1.95%	+7.06%	+108.59%	-18.67%	32.89B
BIONTECH SE	-0.92%	-2.54%	+28.74%	-33.21%	27.09B
INSMED INCORPORATED	-1.55%	+4.46%	+34.99%	+333.64%	19.48B
SUMMIT THERAPEUTICS INC.	-5.18%	+4.80%	+198.24%	+2,239.29%	19.46B
AKESO, INC.	+0.86%	+24.29%	+249.57%	+515.75%	16.09B
GENMAB A/S	-0.07%	+3.01%	-23.33%	-44.07%	13.63B
EXELIXIS, INC.	-0.89%	-0.87%	+96.77%	+103.62%	12.13B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.09%	+14.29%	+159.07%	-	11.32B
Average	-0.36%	+6.29%	+102.22%	+340.98%	20.2B
Weighted average by Cap.	-0.28%	+5.32%	+91.03%	+303.24%

	2025 *	2026 *
Net sales	21.22B 23.2B 2.96B 2.54B 2.36B 2.2B 4.06B 255B 4.53B 28.55B 10.78B 119B 11.09B 10.86B 439B	24.37B 26.63B 3.39B 2.91B 2.71B 2.52B 4.66B 292B 5.2B 32.78B 12.37B 137B 12.73B 12.47B 504B
Net income	4B 4.38B 558M 478M 446M 415M 765M 48.02B 854M 5.39B 2.03B 22.52B 2.09B 2.05B 82.77B	4.74B 5.18B 660M 566M 528M 491M 906M 56.85B 1.01B 6.37B 2.41B 26.65B 2.48B 2.42B 97.97B
Net Debt	-5.13B -5.61B -714M -613M -571M -531M -980M -61.53B -1.09B -6.9B -2.6B -28.85B -2.68B -2.62B -106B	-6.58B -7.19B -916M -786M -733M -682M -1.26B -78.92B -1.4B -8.85B -3.34B -37B -3.44B -3.37B -136B